Company Description

Treos Bio is a clinical-stage company introducing a computational, biomarker-guided approach to cancer immunotherapy to address patient and tumour heterogeneity. They use proprietary therapeutic peptides, manufactured via commercially scalable processes without the need for tumour biopsy, to stimulate cancer-specific immune responses in patients predicted by our diagnostic tests to respond.